SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020-January 2021

被引：85

作者：

Murhekar, Manoj, V ^{[1
]}

Bhatnagar, Tarun ^{[1
]}

Thangaraj, Jeromie Wesley Vivian ^{[1
]}

Saravanakumar, V ^{[1
]}

Kumar, Muthusamy Santhosh ^{[1
]}

Selvaraju, Sriram ^{[2
]}

Rade, Kiran ^{[3
]}

Kumar, C. P. Girish ^{[1
]}

Sabarinathan, R. ^{[1
]}

Turuk, Alka ^{[4
]}

Asthana, Smita ^{[5
]}

Balachandar, Rakesh ^{[6
]}

Bangar, Sampada Dipak ^{[7
]}

Bansal, Avi Kumar ^{[8
]}

Chopra, Vishal ^{[9
]}

Das, Dasarathi ^{[10
]}

Deb, Alok Kumar ^{[11
]}

Devi, Kangjam Rekha ^{[12
]}

Dhikav, Vikas ^{[13
]}

Dwivedi, Gaurav Raj ^{[14
]}

Khan, S. Muhammad Salim ^{[15
]}

Kumar, M. Sunil ^{[16
]}

Laxmaiah, Avula ^{[17
]}

Madhukar, Major ^{[18
]}

Mahapatra, Amarendra ^{[10
]}

Rangaraju, Chethana ^{[19
]}

Turuk, Jyotirmayee ^{[10
]}

Yadav, Rajiv ^{[20
]}

Andhalkar, Rushikesh ^{[2
]}

Arunraj, K. ^{[2
]}

Bharadwaj, Dinesh Kumar ^{[17
]}

Bharti, Pravin ^{[20
]}

Bhattacharya, Debdutta ^{[10
]}

Bhat, Jyothi ^{[20
]}

Chahal, Ashrafjit S. ^{[9
]}

Chakraborty, Debjit ^{[11
]}

Chaudhury, Anshuman ^{[2
]}

Deval, Hirawati ^{[14
]}

Dhatrak, Sarang ^{[6
]}

Dayal, Rakesh ^{[21
]}

Elantamilan, D. ^{[13
]}

Giridharan, Prathiksha ^{[2
]}

Haq, Inaamul ^{[15
]}

Hudda, Ramesh Kumar ^{[13
]}

Jagjeevan, Babu ^{[17
]}

Kalliath, Arshad ^{[16
]}

Kanungo, Srikanta ^{[10
]}

Krishnan, Nivethitha N. ^{[2
]}

Kshatri, Jaya Singh ^{[10
]}

Kumar, Alok ^{[2
]}

机构：

[1] ICMR Natl Inst Epidemiol, Chennai 600077, Tamil Nadu, India

[2] ICMR Natl Inst Res TB, Chennai, Tamil Nadu, India

[3] Who Country Off India, New Delhi, India

[4] Indian Council Med Res, New Delhi, India

[5] ICMR Natl Inst Canc Prevent & Res, Noida, Uttar Pradesh, India

[6] ICMR Natl Inst Occupat Hlth, Ahmadabad, Gujarat, India

[7] ICMR Natl AIDS Res Inst, Pune, Maharashtra, India

[8] ICMR Natl JALMA Inst Leprosy & Other Mycobacteria, Agra, Uttar Pradesh, India

[9] State TB Training & Demonstrat Ctr, Patiala, Punjab, India

[10] ICMR Reg Med Res Ctr, Bhubaneswar, Odisha, India

[11] ICMR Natl Inst Cholera & Enter Dis, Kolkata, W Bengal, India

[12] ICMR Reg Med Res Ctr, Dibrugarh, Assam, India

[13] ICMR Natl Inst Implementat Res Noncommunicable Di, Jodhpur, Rajasthan, India

[14] ICMR Reg Med Res Ctr, Gorakhpur, Uttar Pradesh, India

[15] Govt Med Coll Srinagar, Jammu, Jammu & Kashmir, India

[16] State TB Training & Demonstrat Ctr, Thiruvananthapuram, Kerala, India

[17] ICMR Natl Inst Nutr, Hyderabad, Telangana, India

[18] ICMR Rajendra Mem Res Inst Med Sci, Patna, Bihar, India

[19] Bangalore & Lady Willingdon State TB Ctr, Natl TB Inst, Bengaluru, Karnataka, India

[20] ICMR Natl Inst Res Tribal Hlth, Jabalpur, Madhya Pradesh, India

[21] State TB Training & Demonstrat Ctr, Ranchi, Bihar, India

[22] State TB Off, Hyderabad, Andhra Pradesh, India

[23] State TB Training & Demonstrat Ctr, Raipur, Madhya Pradesh, India

来源：

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2021年 / 108卷

关键词：

SARS-CoV-2; COVID-19; IgG; Seroprevalence; India; PREVALENCE;

D O I：

10.1016/j.ijid.2021.05.040

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Background: Earlier serosurveys in India revealed seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) of 0.73% in May-June 2020 and 7.1% in August-September 2020. A third serosurvey was conducted between December 2020 and January 2021 to estimate the seroprevalence of SARS-CoV-2 infection among the general population and healthcare workers (HCWs) in India. Methods: The third serosurvey was conducted in the same 70 districts as the first and second serosurveys. For each district, at least 400 individuals aged >10 years from the general population and 100 HCWs from subdistrict-level health facilities were enrolled. Serum samples from the general population were tested for the presence of immunoglobulin G (IgG) antibodies against the nucleocapsid (N) and spike (S1-RBD) proteins of SARS-CoV-2, whereas serum samples from HCWs were tested for anti-S1-RBD. Weighted seroprevalence adjusted for assay characteristics was estimated. Results: Of the 28,598 serum samples from the general population, 4585 (16%) had IgG antibodies against the N protein, 6647 (23.2%) had IgG antibodies against the S1-RBD protein, and 7436 (26%) had IgG antibodies against either the N protein or the S1-RBD protein. Weighted and assay-characteristic adjusted seroprevalence against either of the antibodies was 24.1% [95% confidence interval (CI) 23.0- 25.3%]. Among 7385 HCWs, the seroprevalence of anti-S1-RBD IgG antibodies was 25.6% (95% CI 23.5- 27.8%). Conclusions: Nearly one in four individuals aged >10 years from the general population as well as HCWs in India had been exposed to SARS-CoV-2 by December 2020. (c) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).

引用

页码：145 / 155

页数：11

共 28 条

[1] SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline [J].

Bolotin, Shelly ;

Tran, Vanessa ;

Osman, Selma ;

Brown, Kevin A. ;

Buchan, Sarah A. ;

Joh, Eugene ;

Deeks, Shelley L. ;

Allen, Vanessa G. .

JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (08) :1334-1338

[2]

Center for Devices and Radiological Health, 2021, EUA AUTH SER TEST PE

[3] Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan [J].

Chan, Jasper Fuk-Woo ;

Kok, Kin-Hang ;

Zhu, Zheng ;

Chu, Hin ;

To, Kelvin Kai-Wang ;

Yuan, Shuofeng ;

Yuen, Kwok-Yung .

EMERGING MICROBES & INFECTIONS, 2020, 9 (01) :221-236

[4]

Chen XH, 2021, LANCET GLOB HEALTH, V9, pE598, DOI [10.1016/S2214-109X(21)00026-7, 10.1101/2020.09.11.20192773]

[5]

FETP Network-Chennai India, 2021, COVID 19 RES CTR EP

[6]

Galanis P, J HOSP INFECT, V108, P120

[7] Laboratory surveillance for SARS-CoV-2 in India: Performance of testing & descriptive epidemiology of detected COVID-19, January 22-April 30, 2020 [J].

Abraham P. ;

Aggarwal N. ;

Babu G.R. ;

Barani S. ;

Bhargava B. ;

Bhatnagar T. ;

Dhama A.S. ;

Gangakhedkar R.R. ;

Giri S. ;

Gupta N. ;

Kurup K.K. ;

Murhekar M. ;

Potdar V. ;

Praharaj I. ;

Rade K. ;

Reddy D.C.S. ;

Saravanakumar V. ;

Shah N. ;

Singh H. ;

Thangaraj J.W.V. ;

Yadav N. .

INDIAN JOURNAL OF MEDICAL RESEARCH, 2020, 151 (05) :424-437

[8]

Indian Council of Medical Research, 2017, NAT ETH GUID BIOM RE

[9] Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay [J].

Irsara, Christian ;

Egger, Alexander E. ;

Prokop, Wolfgang ;

Nairz, Manfred ;

Loacker, Lorin ;

Sahanic, Sabina ;

Pizzini, Alex ;

Sonnweber, Thomas ;

Mayer, Wolfgang ;

Schennach, Harald ;

Loeffler-Ragg, Judith ;

Bellmann-Weiler, Rosa ;

Tancevski, Ivan ;

Weiss, Guenter ;

Anliker, Markus ;

Griesmacher, Andrea ;

Hoermann, Gregor .

CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2021, 59 (06) :1143-1154

[10] COVID-19: Challenges and its consequences for rural health care in India [J].

Kumar, Anant ;

Nayar, K. Rajasekharan ;

Koya, Shaffi Fazaludeen .

PUBLIC HEALTH IN PRACTICE, 2020, 1

← 1 2 3 →